272 related articles for article (PubMed ID: 27389437)
1. No increased risk of hospitalization for heart failure for patients treated with dipeptidyl peptidase-4 inhibitors in Taiwan.
Chang CH; Chang YC; Lin JW; Caffrey JL; Wu LC; Lai MS; Chuang LM
Int J Cardiol; 2016 Oct; 220():14-20. PubMed ID: 27389437
[TBL] [Abstract][Full Text] [Related]
2. Dipeptidyl peptidase-4 inhibitors and heart failure: Analysis of spontaneous reports submitted to the FDA Adverse Event Reporting System.
Raschi E; Poluzzi E; Koci A; Antonazzo IC; Marchesini G; De Ponti F
Nutr Metab Cardiovasc Dis; 2016 May; 26(5):380-6. PubMed ID: 27067162
[TBL] [Abstract][Full Text] [Related]
3. Do dipeptidyl peptidase IV (DPP-IV) inhibitors cause heart failure?
Clifton P
Clin Ther; 2014 Dec; 36(12):2072-2079. PubMed ID: 25453730
[TBL] [Abstract][Full Text] [Related]
4. Association Between Hospitalization for Heart Failure and Dipeptidyl Peptidase 4 Inhibitors in Patients With Type 2 Diabetes: An Observational Study.
Fu AZ; Johnston SS; Ghannam A; Tsai K; Cappell K; Fowler R; Riehle E; Cole AL; Kalsekar I; Sheehan J
Diabetes Care; 2016 May; 39(5):726-34. PubMed ID: 26740636
[TBL] [Abstract][Full Text] [Related]
5. Dipeptidyl Peptidase-4 Inhibitors and Risk of Heart Failure in Patients With Type 2 Diabetes Mellitus: A Population-Based Cohort Study.
Kim YG; Yoon D; Park S; Han SJ; Kim DJ; Lee KW; Park RW; Kim HJ
Circ Heart Fail; 2017 Sep; 10(9):. PubMed ID: 28899989
[TBL] [Abstract][Full Text] [Related]
6. Increased risk of bullous pemphigoid in dipeptidyl peptidase 4 inhibitors: A nationwide, population-based, cohort study in Taiwan.
Hung CT; Liu JS; Cheng CY; Chung CH; Chiang CP; Chien WC; Wang WM
J Dermatol; 2020 Mar; 47(3):245-250. PubMed ID: 31885117
[TBL] [Abstract][Full Text] [Related]
7. Differences in baseline characteristics between type 2 diabetes mellitus patients treated with dipeptidyl peptidase-4 inhibitors in randomized controlled trials and those receiving the same treatment in real-world settings
.
Kostev K; Schokker E; Jacob L
Int J Clin Pharmacol Ther; 2018 Sep; 56(9):411-416. PubMed ID: 30049306
[TBL] [Abstract][Full Text] [Related]
8. Assessment of the Risk of Hospitalization for Heart Failure With Dipeptidyl Peptidase-4 Inhibitors, Saxagliptin, Alogliptin, and Sitagliptin in Patients With Type 2 Diabetes, Using an Alternative Measure to the Hazard Ratio.
Kaneko M; Narukawa M
Ann Pharmacother; 2017 Jul; 51(7):570-576. PubMed ID: 28622738
[TBL] [Abstract][Full Text] [Related]
9. Healthcare Costs Among Adults with Type 2 Diabetes Initiating DPP-4 Inhibitors.
Farr AM; Sheehan JJ; Brouillette M; Smith DM; Johnston SS; Kalsekar I
Adv Ther; 2016 Jan; 33(1):68-81. PubMed ID: 26724938
[TBL] [Abstract][Full Text] [Related]
10. Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus.
Richter B; Bandeira-Echtler E; Bergerhoff K; Lerch CL
Cochrane Database Syst Rev; 2008 Apr; 2008(2):CD006739. PubMed ID: 18425967
[TBL] [Abstract][Full Text] [Related]
11. Adherence, Persistence, and Health Care Costs for Patients Receiving Dipeptidyl Peptidase-4 Inhibitors.
Rascati KL; Worley K; Meah Y; Everhart D
J Manag Care Spec Pharm; 2017 Mar; 23(3):299-306. PubMed ID: 28230454
[TBL] [Abstract][Full Text] [Related]
12. Dipeptidyl peptidase-4 inhibitors and cardiovascular risks in patients with pre-existing heart failure.
Ou SM; Chen HT; Kuo SC; Chen TJ; Shih CJ; Chen YT
Heart; 2017 Mar; 103(6):414-420. PubMed ID: 27647170
[TBL] [Abstract][Full Text] [Related]
13. Hypoglycemia hospitalization frequency in patients with type 2 diabetes mellitus: a comparison of dipeptidyl peptidase 4 inhibitors and insulin secretagogues using the French health insurance database.
Detournay B; Halimi S; Robert J; Deschaseaux C; Dejager S
Vasc Health Risk Manag; 2015; 11():417-25. PubMed ID: 26229480
[TBL] [Abstract][Full Text] [Related]
14. Retrospective analysis of long-term adherence to and persistence with DPP-4 inhibitors in US adults with type 2 diabetes mellitus.
Farr AM; Sheehan JJ; Curkendall SM; Smith DM; Johnston SS; Kalsekar I
Adv Ther; 2014 Dec; 31(12):1287-305. PubMed ID: 25504156
[TBL] [Abstract][Full Text] [Related]
15. Effect of Dipeptidyl Peptidase-4 Inhibitors on Heart Failure: A Network Meta-Analysis.
Guo WQ; Li L; Su Q; Dai WR; Ye ZL
Value Health; 2017 Dec; 20(10):1427-1430. PubMed ID: 29241903
[TBL] [Abstract][Full Text] [Related]
16. Impact of dipeptidyl peptidase-4 inhibitors on serum adiponectin: a meta-analysis.
Liu X; Men P; Wang Y; Zhai S; Liu G
Lipids Health Dis; 2016 Nov; 15(1):204. PubMed ID: 27881129
[TBL] [Abstract][Full Text] [Related]
17. Risk for Hospitalized Heart Failure Among New Users of Saxagliptin, Sitagliptin, and Other Antihyperglycemic Drugs: A Retrospective Cohort Study.
Toh S; Hampp C; Reichman ME; Graham DJ; Balakrishnan S; Pucino F; Hamilton J; Lendle S; Iyer A; Rucker M; Pimentel M; Nathwani N; Griffin MR; Brown NJ; Fireman BH
Ann Intern Med; 2016 Jun; 164(11):705-14. PubMed ID: 27110660
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of vildagliptin and sitagliptin in lowering fasting plasma glucose: Results of a randomized controlled trial.
Göke R; Eschenbach P; Dütting ED
Diabetes Metab; 2015 Jun; 41(3):244-7. PubMed ID: 25457473
[TBL] [Abstract][Full Text] [Related]
19. Sitagliptin and cardiovascular outcomes in diabetic patients with chronic kidney disease and acute myocardial infarction: A nationwide cohort study.
Chen DY; Wang SH; Mao CT; Tsai ML; Lin YS; Chou CC; Wen MS; Wang CC; Hsieh IC; Hung KC; Chen TH
Int J Cardiol; 2015 Feb; 181():200-6. PubMed ID: 25528312
[TBL] [Abstract][Full Text] [Related]
20. Dipeptidyl peptidase-4 inhibitors and heart failure: a meta-analysis of randomized clinical trials.
Monami M; Dicembrini I; Mannucci E
Nutr Metab Cardiovasc Dis; 2014 Jul; 24(7):689-97. PubMed ID: 24793580
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
